Rapport Therapeutics, Inc.
RAPP
$27.60
$0.481.77%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -53.53% | -47.52% | -6.15% | -47.79% | -101.37% |
| Total Depreciation and Amortization | 16.89% | 21.15% | 60.53% | 390.57% | 852.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 298.99% | 183.85% | -50.18% | 237.60% | 41.10% |
| Change in Net Operating Assets | 875.26% | -2,639.84% | 86.28% | -31.02% | -120.88% |
| Cash from Operations | -6.40% | -53.31% | -14.89% | -39.48% | -202.64% |
| Capital Expenditure | 4.29% | 97.72% | 72.85% | 84.27% | -169.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.07% | 121.31% | 152.19% | 141.64% | -- |
| Cash from Investing | -7.04% | 121.10% | 150.16% | 140.59% | -101,901.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -34,750.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -122.26% | -- | -- | -- |
| Cash from Financing | 19,506.96% | -100.04% | -99.99% | 105.00% | -101.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 377.05% | -107.07% | -80.60% | 119.62% | -188.69% |